Isfahan University of Medical Sciences
mui.ac.irLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
149
Active
9
Phase 3
40
Total enrollment
28,873
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| bevacizumab with oral curcumin | — | — | — | — | — | 1 | |
| bevacizumab with oral placebo | — | — | — | — | — | 1 | |
| Ev.FV 1.0 x 1011 par/ml | — | — | — | — | — | 1 | |
| Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the "Zyest Technology Tarawat Zendig" institute in Iran. The dosage of ASX is determined based on the s | — | — | — | — | — | 1 | |
| Exosome | — | — | — | — | 2 |
Next readouts
- 2025-07-22
- 2025-09-22
- 2025-12-01
- 2026-12-25
Top conditions
- Tangier Disease3
- Multiple Sclerosis3
- Local Anesthesia3
- Fatigue2
- Nutritional and Metabolic Disease2
- Education2
- Education, Medical2
- Education, Medical, Undergraduate2
Frequently asked questions about Isfahan University of Medical Sciences
- How many clinical trials does Isfahan University of Medical Sciences have on ClinicalTrials.gov?
- Isfahan University of Medical Sciences is listed as the lead sponsor on 149 clinical trials in ClinicalTrials.gov, 9 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Isfahan University of Medical Sciences's trials are in Phase 3?
- 40 of Isfahan University of Medical Sciences's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Isfahan University of Medical Sciences focus on?
- Isfahan University of Medical Sciences's most-studied conditions on ClinicalTrials.gov are Tangier Disease, Multiple Sclerosis, Local Anesthesia, Fatigue, Nutritional and Metabolic Disease.
- When are Isfahan University of Medical Sciences's next clinical trial readouts?
- Isfahan University of Medical Sciences has 4 upcoming primary-completion readouts tracked here; the soonest is “The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Polycystic Ovary Syndrome”, expected around 2025-07-22.